This research is Trending!
July 6, 2026Circulation
Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis: Two-Year Follow-Up of the AGENT-IDE Randomized Clinical Trial
Jeffrey W. MosesJiho HanRichard ShlofmitzWilliam BachinskySuhail DohadSteven RudickRobert C. StolerBrian K. JeffersonWilliam J. NicholsonJohn AltmanCinthia BatemanAmar KrishnaswamyJ. Aaron GranthamFrank ZidarJennifer A. TremmelCindy L. GrinesMustafa AhmedAzeem LatibBehnam TehraniJ. Dawn AbbottWayne BatchelorRafael CavalcanteAjay J. KirtaneRobert W. Yehon behalf of the AGENT IDE Investigators
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The easy one is multi-layer stenting. Most of us are quite hesitant to add a third layer. Smaller vessels also, [it is] a matter of real estate, and I also see complex bifurcation restenoses which are pretty common. Those are the sweet spots.”
“Consistent results were observed on the 2-year follow-up, with a significantly reduced instance of target lesion failure, with a 37% [relative risk] reduction.”
“It'll be very important for cardiologists to be meticulous in applying best practices for treating in-stent restenosis lesions prior to using a drug-coated balloon.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Moses et al. (2026) studied this question.